SCHEMBL16068151

SCHEMBL16068151

CC1CN(c2ccc(-c3nc4ccncc4n3-c3ccc(F)cc3)cn2)CCO1

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 18/20 0.75
▸ KCNH2 Q12809 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25765353 0.93 AOC3 (0.76) AOC3KCNH2
SCHEMBL25764898 0.91 AOC3 (0.65) AOC3KCNH2
SCHEMBL22001001 0.89 AOC3 (0.64) AOC3KCNH2
SCHEMBL16047562 0.86 AOC3 (1.00) AOC3KCNH2
SCHEMBL30026916 0.86 AOC3 (1.00) AOC3KCNH2
SCHEMBL22997141 0.82 AOC3 (0.53) AOC3KCNH2
SCHEMBL25765366 0.81 AOC3 (0.53) AOC3KCNH2
SCHEMBL17611248 0.80 AOC3 (0.78) AOC3KCNH2
SCHEMBL16067614 0.80 AOC3 (0.78) AOC3KCNH2
SCHEMBL23870667 0.80 AOC3 (0.74) AOC3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 — — US claimed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 — — US claimed
US-20200147059-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS PROXIMAGEN, LLC (US) 2020-05-14 — — US claimed
EP-3634393-A1 INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE PROXIMAGEN, LLC (US) 2020-04-15 — — EP claimed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 — — US claimed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 — — EP claimed
WO-2018224837-A1 INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE Proximagen Group Limited (GB) 2018-12-13 — — WO claimed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 — — US claimed
US-20230190728-A1 NEW THERAPEUTIC USES OF COMPOUNDS PROXIMAGEN LLC (US) 2023-06-22 — — US disclosed
US-20230190728-A1 NEW THERAPEUTIC USES OF COMPOUNDS PROXIMAGEN LLC (US) 2023-06-22 — — US disclosed
US-20230190728-A1 NEW THERAPEUTIC USES OF COMPOUNDS PROXIMAGEN LLC (US) 2023-06-22 — — US disclosed
WO-2021195406-A1 NEW THERAPEUTIC USES OF COMPOUNDS PROXIMAGEN, LLC (US) 2021-09-30 — — WO disclosed
WO-2021195406-A1 NEW THERAPEUTIC USES OF COMPOUNDS PROXIMAGEN, LLC (US) 2021-09-30 — — WO disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 — — US disclosed
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2016-02-18 — — US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed
WO-2014140592-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LIMITED (GB) 2014-09-18 — — WO disclosed
US-8680062-B2 System for delivering therapeutic agents into living cells and cells nuclei Deliversir Ltd. (IL) 2014-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH AOC3 10/4885KCNH2 364/4885
US-20230190728-A1 NEW THERAPEUTIC USES OF COMPOUNDS ACE2, TMPRSS2, IL1B AOC3 2604/4885KCNH2 800/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 AOC3 7/4885KCNH2 448/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 AOC3 7/4885KCNH2 448/4885
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, AOC3, IL4I1 AOC3 2/4885KCNH2 570/4885
US-20200147059-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS VAPB, VAPA, SMOX AOC3 4/4885KCNH2 1505/4885
US-20150258101-A1 NEW COMPOUNDS AOX1, QSOX1, MAOB AOC3 85/4885KCNH2 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback